Clinical trial
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous…
NCT00129740 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00129740 |
|---|---|
| Title | Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) |
| Official title | Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelogenous, Chronic |
| Intervention type | Drug |
| Interventions | Nilotinib |
| Enrollment | 148 |
| Start date | Jun 27, 2005 |
| Primary completion | Jul 11, 2018 |
| Completion | Jul 11, 2018 |
| First posted | Aug 12, 2005 |
| Last update posted | Sep 24, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: